Education
About Us
Working with TipRanks
Follow Us
Amgen (DE:AMG)
XETRA:AMG
AMG Stock Chart & Stats
Day’s Range― - ―
52-Week Range€243.30 - €318.05
Previous CloseN/A
Volume4.00
Average Volume (3M)658.00
Market Cap
$161.04B
Enterprise Value€190.17B
Total Cash (Recent Filing)$11.97B
Total Debt (Recent Filing)$60.10B
Price to Earnings (P/E)42.9
Beta0.05
Next Earnings
Apr 23, 2025EPS Estimate
3.96Next Dividend Ex-Date
May 16, 2025Dividend Yield2.81%
Share Statistics
EPS (TTM)6.92
Shares Outstanding537,204,960
10 Day Avg. Volume1,010
30 Day Avg. Volume658
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)5.22
Price to Cash Flow (P/CF)9.10
P/FCF Ratio8.10
Enterprise Value/Market Cap1.18
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit9.25
Enterprise Value/Ebitda14.24
Forecast
1Y Price Target
€304.45Price Target Upside1.45% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering17
---
Bulls Say, Bears Say
Bulls Say
Financial PerformanceNon-GAAP EPS of $5.31 exceeded expectations, indicating strong financial performance.
Product PerformanceRepatha and Tezspire have been experiencing significant growth, with Repatha growing 35% year-over-year on volume and Tezspire growing 70% year-over-year.
Bears Say
Valuation ConcernsThe company trades at a P/E multiple that is slightly above average, with a LT growth profile that is at or below average.
---
Options Prices
Currently, No data available
---
Ownership Overview
0.18% Insiders
21.42% Mutual Funds
16.44% Other Institutional Investors
34.65% Public Companies and Individual Investors
AMG FAQ
What was Amgen’s price range in the past 12 months?
Amgen lowest stock price was €243.30 and its highest was €318.05 in the past 12 months.
What is Amgen’s market cap?
Amgen’s market cap is $161.04B.
When is Amgen’s upcoming earnings report date?
Amgen’s upcoming earnings report date is Apr 23, 2025 which is in 42 days.
How were Amgen’s earnings last quarter?
Amgen released its earnings results on Feb 04, 2025. The company reported €4.9 earnings per share for the quarter, beating the consensus estimate of €4.698 by €0.202.
Is Amgen overvalued?
According to Wall Street analysts Amgen’s price is currently Undervalued.
Does Amgen pay dividends?
Amgen pays a Quarterly dividend of €2.196 which represents an annual dividend yield of 2.81%. See more information on Amgen dividends here
What is Amgen’s EPS estimate?
Amgen’s EPS estimate is 3.96.
How many shares outstanding does Amgen have?
Amgen has 537,204,960 shares outstanding.
What happened to Amgen’s price movement after its last earnings report?
Amgen reported an EPS of €4.9 in its last earnings report, beating expectations of €4.698. Following the earnings report the stock price went up 4.744%.
Which hedge fund is a major shareholder of Amgen?
Currently, no hedge funds are holding shares in DE:AMG
---
Amgen Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
€304.45 (1.45% Upside)
€304.45 (1.45% Upside)
Blogger Sentiment
Bullish
DE:AMG Sentiment 87%
Sector Average 70%
Sector Average 70%
Insider Transactions
Sold Shares
Worth $20.7M over
the Last 3 Months
the Last 3 Months
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
22.68%
12-Months-Change
Fundamentals
Return on Equity
67.55%
Trailing 12-Months
Asset Growth
-5.47%
Trailing 12-Months
Company Description
Amgen
Founded in 1980, California-based Amgen, Inc. is one of the world's leading biotechnology companies, which is engaged in the discovery, development, manufacture and marketing of human therapeutics. It primarily focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology and neuroscience areas.
---
AMG Company Deck
---
AMG Earnings Call
Q4 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call reflected a strong performance in 2024 with significant growth in product sales, particularly in oncology and biosimilars. The successful integration of Horizon and robust financial results further reinforce Amgen's position for continued growth. However, challenges such as the upcoming patent expiration for denosumab and expected price declines pose potential risks.Read More>---
AMG Revenue Breakdown
13.09% Prolia
9.92% Enbrel
6.66% XGEVA
6.65% Repatha
63.69% Other
---
AMG Stock 12 Month Forecast
Average Price Target
€304.45
▲(1.45% Upside)
Technical Analysis
Best Analysts Covering AMG
1 Year
1 Year Success Rate
29/35 ratings generated profit
1 Year Average Return
+15.34%
reiterated a buy rating 2 days ago
Copying Yaron Werber's trades and holding each position for 1 Year would result in 82.86% of your transactions generating a profit, with an average return of +15.34% per trade.
---